Effective suppression of the kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering rna delivery using nanoparticles

Pancreas

Volumn 44, Issue 2, 2015, Pages 250-259

  Zeng, Linjuan ^a,b   Li, Jingguo ^c,d   Li, Jiajia ^a   Zhang, Qiubo ^e   Qian, Chenchen ^a   Wu, Wei ^b   Lin, Zhong ^b   Liang, Jianzhong ^f   Chen, Yinting ^a   Huang, Kaihong ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Henan Eye Institute   (China)

^e Lihuili Hospital of Ningbo Medical Center   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD44 variant 6; In vivo imaging; Nanoparticles; Pancreatic tumor; Small interfering RNA; Tumor targeting

Indexed keywords

CD44V6 ANTIGEN; K RAS PROTEIN; MACROGOL; NANOPARTICLE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; VASCULOTROPIN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; KRAS PROTEIN, HUMAN; LYSINE; MACROGOL DERIVATIVE; MICELLE; ONCOPROTEIN; POLY(ETHYLENE GLYCOL) LYSINE COPOLYMER; RAS PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICELLE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; U937 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; NANOMEDICINE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TIME; TUMOR INVASION;

ANIMALS; ANTIGENS, CD44; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; LYSINE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOMEDICINE; NANOPARTICLES; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925844178     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000241     Document Type: Article

References (45)

1. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988; 16: 7773-7782.
2. Morris JT, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010; 10: 683-695.
3. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7: 295-308.
4. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806-811.
5. Wang J, Lu Z, WientjesMG, et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010; 12: 492-503.
6. Katakura H, Harada A, Kataoka K, et al. Improvement of retroviral vectors by coating with poly(ethylene glycol)-poly(L-lysine) block copolymer (PEG-PLL). J GeneMed. 2004; 6: 471-477.
7. Harada-Shiba M, Yamauchi K, Harada A, et al. Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther. 2002; 9: 407-414.
8. Shiraishi K, Kawano K, Minowa T, et al. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J Control Release. 2009; 136: 14-20.
9. Wolfert MA, Schacht EH, Toncheva V, et al. Characterization of vectors for gene therapy formed by self-assembly of DNAwith synthetic block co-polymers. Hum Gene Ther. 1996; 7: 2123-2133.
10. Choi YR, Chae SY, Ahn CH, et al. Development of polymeric gene delivery carriers: PEGylated copolymers of L-lysine and L-phenylalanine. J Drug Target. 2007; 15: 391-398.
11. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008; 105: 2586-2591.
12. Okayama H, Kumamoto K, Saitou K, et al. CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 2009; 22: 745-755.
13. Stroomer JW, Roos JC, Sproll M, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res. 2000; 6: 3046-3055.
14. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer. 2002; 99: 396-402.
15. Zhou G, Chiu D, Qin D, et al. Detection and clinical significance of CD44v6 and integrin-beta1 in pancreatic cancer patients using a triplex real-time RT-PCR assay. Appl Biochem Biotechnol. 2012; 167: 2257-2268.
16. Gansauge F, Gansauge S, Zobywalski A, et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res. 1995; 55: 5499-5503.
17. Chen Y, Huang K, Li X, et al. Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro. Cancer Immunol Immunother. 2010; 59: 933-942.
18. Zeng L, Li J, Wang Y, et al. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine. 2014; 10: 463-472.
19. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010; 39: 425-435.
20. Chen G, Chen W, Wu Z, et al. MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials. 2009; 30: 1962-1970.
21. Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 2011; 716: 157-168.
22. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007; 120: 1444-1450.
23. Al-Nasiry S, Geusens N, HanssensM, et al. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod. 2007; 22: 1304-1309.
24. Rokavec M, WuW, Luo JL. IL6-mediated suppression ofmiR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell. 2012; 45: 777-789.
25. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3: 11-22.
26. Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011; 19: 541-555.
27. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69: 7507-7511.
28. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004; 64: 8420-8427.
29. Shields JM, Pruitt K, McFall A, et al. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 2000; 10: 147-154.
30. Zhang YA, Nemunaitis J, Samuel SK, et al. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006; 66: 9736-9743.
31. Fleming JB, Shen GL, Holloway SE, et al. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005; 3: 413-423.
32. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002; 2: 243-247.
33. Jung T, Gross W, Zoller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem. 2011; 286: 15862-15874.
34. Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002; 16: 3074-3086.
35. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J ExpMed. 1993; 177: 443-455.
36. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011; 63: 136-151.
37. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-6392.
38. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7: 653-664.
39. Ray A, Larson N, Pike DB, et al. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm. 2011; 8: 1090-1099.
40. KanoMR, Komuta Y, Iwata C, et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009; 100: 173-180.
41. Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res. 2008; 14: 5995-6004.
42. Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21: 488-503.
43. Michl P, Gress TM. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut. 2012; 61: 1377-1379.
44. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with ?K-Ras addiction? reveals regulators of EMTand tumor cell survival. Cancer Cell. 2009; 15: 489-500.
45. Cao N, Cheng D, Zou S, et al. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011; 32: 2222-2232.